KPIs & Operating Metrics(New)
Growth Metrics

Amgen (AMGN) Non-Current Deferred Tax Liability (2016 - 2025)

Historic Non-Current Deferred Tax Liability for Amgen (AMGN) over the last 12 years, with Q4 2025 value amounting to $3.2 billion.

  • Amgen's Non-Current Deferred Tax Liability fell 299.58% to $3.2 billion in Q4 2025 from the same period last year, while for Dec 2025 it was $3.2 billion, marking a year-over-year decrease of 299.58%. This contributed to the annual value of $3.2 billion for FY2025, which is 299.58% down from last year.
  • Per Amgen's latest filing, its Non-Current Deferred Tax Liability stood at $3.2 billion for Q4 2025, which was down 299.58% from $1.5 billion recorded in Q3 2025.
  • Amgen's Non-Current Deferred Tax Liability's 5-year high stood at $4.1 billion during Q4 2023, with a 5-year trough of $1.4 billion in Q2 2025.
  • Over the past 4 years, Amgen's median Non-Current Deferred Tax Liability value was $1.8 billion (recorded in 2024), while the average stood at $2.2 billion.
  • As far as peak fluctuations go, Amgen's Non-Current Deferred Tax Liability skyrocketed by 11897.65% in 2023, and later crashed by 2213.48% in 2025.
  • Quarter analysis of 4 years shows Amgen's Non-Current Deferred Tax Liability stood at $1.9 billion in 2022, then skyrocketed by 118.98% to $4.1 billion in 2023, then decreased by 18.74% to $3.3 billion in 2024, then decreased by 3.0% to $3.2 billion in 2025.
  • Its Non-Current Deferred Tax Liability stands at $3.2 billion for Q4 2025, versus $1.5 billion for Q3 2025 and $1.4 billion for Q2 2025.